Investor Backing & Capital Strength:
Investor support is underscored by a sizable Series C round and notable growth recognitions, signaling confidence in scaling. Feedback suggests this capital is being directed to expand platforms and AI-powered products aligned to modernization of prior authorization.
Strategic Partnerships:
Major national and regional payers have expanded production deployments, including Humana’s added service lines and several Blues and Medical Mutual notices directing providers to Cohere. These plan-wide programs indicate embedded relationships beyond pilots.
Product Line Growth:
The platform has broadened beyond core prior authorization into areas like payment integrity, policy automation, and regulatory readiness. Momentum includes launches and integrations that extend clinical decisioning and real-time workflows across adjacent use cases.
